GSA Capital Partners LLP Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

GSA Capital Partners LLP raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 475.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,308 shares of the biopharmaceutical company’s stock after purchasing an additional 30,830 shares during the quarter. GSA Capital Partners LLP’s holdings in Xenon Pharmaceuticals were worth $1,469,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Driehaus Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 2.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock valued at $172,315,000 after purchasing an additional 97,732 shares in the last quarter. Capital International Investors boosted its position in Xenon Pharmaceuticals by 0.8% during the 1st quarter. Capital International Investors now owns 2,475,859 shares of the biopharmaceutical company’s stock valued at $106,586,000 after acquiring an additional 20,176 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Xenon Pharmaceuticals by 18.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 994,227 shares of the biopharmaceutical company’s stock worth $38,765,000 after acquiring an additional 156,840 shares during the period. Lord Abbett & CO. LLC raised its position in shares of Xenon Pharmaceuticals by 24.7% in the 1st quarter. Lord Abbett & CO. LLC now owns 895,196 shares of the biopharmaceutical company’s stock worth $38,539,000 after acquiring an additional 177,224 shares in the last quarter. Finally, TimesSquare Capital Management LLC lifted its stake in shares of Xenon Pharmaceuticals by 3.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 778,293 shares of the biopharmaceutical company’s stock valued at $30,641,000 after purchasing an additional 23,800 shares during the period. 95.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

XENE has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday. Raymond James restated an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $57.45.

Xenon Pharmaceuticals Stock Down 3.3 %

NASDAQ:XENE opened at $41.97 on Thursday. The stock has a market cap of $3.18 billion, a price-to-earnings ratio of -14.88 and a beta of 1.25. The company’s 50 day moving average price is $41.11 and its 200-day moving average price is $40.34. Xenon Pharmaceuticals Inc. has a 52 week low of $28.10 and a 52 week high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the previous year, the company earned ($0.73) EPS. As a group, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.